Phase II: Feasibility assessment of a novel tool for mosquito vector control: Auto-Dissemination Augmented by Males (ADAM)

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44AI112048-02
Agency Tracking Number: R44AI112048
Amount: $597,201.00
Phase: Phase II
Program: SBIR
Awards Year: 2017
Solicitation Year: 2016
Solicitation Topic Code: R
Solicitation Number: PA15-269
Small Business Information
MOSQUITOMATE, INC.
341 GLENDOVER RD, Lexington, KY, 40503-2010
DUNS: 780816091
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 COREY BRELSFOARD
 (859) 327-9733
 cbrelsfoard@mosquitomate.com
Business Contact
 JAMES MAINS
Phone: (859) 429-0501
Email: mosquitomate@gmail.com
Research Institution
N/A
Abstract
Project summary abstract Mosquito control remains the primary tool for combating many mosquito vectored diseases such as Dengue Chikungunya Zika and West Nile because no approved vaccine therapeutant or prophylaxis is currently available for use Key deficiencies of existing vector control methods include resistance to existing insecticides and the inability to find and treat cryptic breeding sites which provide refuge to immature mosquitoes and allow for the rapid recovery of mosquito populations following conventional control efforts The self delivering method known as `auto disseminationandapos addresses this deficiency by using mosquitoes as the vehicle to deliver a potent mosquito growth regulator to cryptic breeding sites The Phase results have included pilot laboratory and field work as a proof of principle against both Aedes aegypti and Aedes albopictus The epidemiology of Zika has led to an urgent need for preemptive vector control approaches Specifically a majority of Zika virus infections in humans are not detected quickly Delayed detection can undermine a public health protection plan that is based on reactive approaches i e a strategy of initiating intensive vector control only after the detection of an epidemic because by the time of detection a large proportion of the human population can be infected already The approach being developed in the proposed work is ideal as a preemptive approach because it requires small amounts of chemical i e less environmental impact and the artificially reared mosquito carriers can be delivered at any time e g before an indigenous vector population reaches dangerous levels The Auto Dissemination Augmented by Males ADAM is based on mass producing male mosquitoes which do not bite or transmit pathogens The ADAM method can utilize wild type mosquitoes Wolbachia infected mosquitoes or Genetically Modified mosquitoes Integration with existing mosquito mass rearing programs can speed the uptake of the ADAM technology Adult ADAM males are treated with an Insect Growth Regulator IGR and then released to deliver lethal doses of the IGR to oviposition sites Phase I work included laboratory development regulatory work e g approval of a Research Authorization from the California Department of Pesticide Regulation field trials in KY against Ae albopictus and field trials in collaboration with the Consolidated Mosquito Abatement District CMAD to test the ADAM approach against Ae aegypti The laboratory results show that Ae albopictus Ae aegypti and Culex pipiens males can tolerate the IGR with negligible cost to the male carriers directly deliver larvicide to breeding sites and cross contaminate females with IGR doses that are subsequently lethal to larvae Field trials with both Ae aegypti and Ae albopictus show the ADAM method to cause significant larval mortality and significant reductions in the adult population when compared to the non treated sites Phase work also included an improvement of methods for the mass manufacturing of adult male mosquitoes In the proposed Phase II work we will conduct work to replicate and expand field trials against Ae aegypti and Ae albopictus from proof of principle trials to a scale that is adequate for operational use by mosquito abatement districts By performing field trials with multiple abatement districts from different states our proposed Phase II work will satisfy an EPA requirement for commercial registration i e that efficacy and safety be demonstrated in multiple ecological contexts In addition to the EPA the data will be submitted to the World Health Organization WHO Vector Control Advisory Group VCAG which serves as an advisory body on new forms of vector control WHO approval is anticipated to increase international uptake of the ADAM technology Additional Phase II work will extend Phase I work with Cx pipiens an important vector of West Nile Virus Specifically one or more field trials will provide efficacy data for use against this additional important mosquito species which is another focus of abatement districtsandapos vector control efforts Narrative Vector control remains the only means to combat many mosquito borne diseases including those caused by Zika West Nile Dengue Chikungunya viruses and other pathogens There is a need to develop additional tools that target immature mosquito populations that remain hidden or protected within cryptic breeding sites and that are inaccessible to conventional control techniques The proposed work will further develop a novel `self deliveringandapos approach that is based on the release of adult male mosquitoes as vehicles to deliver a powerful and safe Insect Growth Regulator

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government